Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 8 · below the Ichimoku cloud · RSI 40 · MACD above its signal · 8% below its 52-week high
None of the 29 investors followed here reported a position in AGNG in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AGNG trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.9 | 3.8 | -7.2 | -1.0 | -0.4 | 2.6 | 3.3 | 2.5 | -4.0 | -1.3 | +0.7% | ||
| 2025 | 4.7 | 2.2 | -3.0 | 0.5 | -0.3 | 1.8 | -0.1 | 4.3 | 0.7 | 1.1 | 8.9 | -2.5 | +18.9% |
| 2024 | -0.6 | 4.3 | 2.1 | -4.6 | 3.5 | 1.2 | 3.4 | 6.7 | -1.0 | -2.5 | -0.2 | -5.5 | +6.2% |
| 2023 | 2.7 | -2.7 | 2.3 | 5.2 | -3.8 | 2.5 | 0.3 | -2.3 | -4.5 | -4.2 | 7.7 | 6.0 | +8.6% |
| 2022 | -7.4 | 1.4 | 6.0 | -7.0 | -1.7 | -3.5 | 3.8 | -6.6 | -4.2 | 6.0 | 6.8 | -1.5 | −9.1% |
| 2021 | 1.0 | -1.4 | -0.2 | 4.4 | 0.7 | 4.6 | -0.0 | 1.5 | -5.6 | 1.8 | -7.6 | 4.8 | +3.2% |
| 2020 | -0.6 | -4.2 | -10.3 | 12.7 | 7.0 | 0.8 | 3.3 | 1.7 | 0.0 | -4.7 | 9.6 | 4.0 | +18.5% |
| 2019 | 9.5 | 3.5 | -0.1 | -3.7 | -2.1 | 5.1 | 1.4 | -0.8 | -0.6 | 5.9 | 5.4 | -0.7 | +24.2% |
| 2018 | 6.8 | -2.7 | -3.1 | -0.4 | 4.4 | 2.1 | 2.6 | 4.4 | 1.4 | -12.7 | 4.0 | -7.4 | −2.5% |
| 2017 | 2.2 | 6.3 | 1.7 | 4.0 | 1.4 | 5.8 | -0.5 | 2.5 | 0.6 | 0.2 | 0.6 | -0.5 | +26.9% |
| 2016 | -1.9 | 0.0 | 7.9 | 1.2 | -10.7 | 1.6 | 0.4 | −2.4% |
The fund invests more than 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that facilitate the demographic trend of longer average life spans and the aging of the global population, including but not limited to companies involved in biotechnology, medical devices, pharmaceuticals, senior living facilities and specialized health care services.
No recent headlines.